Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27430354 | 0.98 | NLRP3 (0.44) | NLRP3CA2 | |
| SCHEMBL19506100 | 0.83 | NLRP3 (0.46) | NLRP3CA2 | |
| Sulfanilamide SCHEMBL7658884 | 0.82 | CA2 (0.42) | NLRP3CA2 | |
| SCHEMBL20692175 | 0.79 | NLRP3 (0.40) | NLRP3CA2 | |
| SCHEMBL22013008 | 0.79 | NLRP3 (0.42) | NLRP3CA2 | |
| SCHEMBL18029662 | 0.77 | NLRP3 (0.57) | NLRP3CA2 | |
| SCHEMBL7208070 | 0.77 | NLRP3 (0.53) | NLRP3CA2 | |
| SCHEMBL19871704 | 0.75 | NLRP3 (0.55) | NLRP3CA2 | |
| SCHEMBL7612982 | 0.74 | NLRP3 (0.90) | NLRP3CA2 | |
| SCHEMBL22265271 | 0.74 | NLRP3 (0.48) | NLRP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023037024-A1 | N-SULFONYLUREA DERIVATIVES AND THE THERAPEUTIC USE THEREOF | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (90%) (ES) | 2023-03-16 | — | — | WO | claimed |
| EP-1270565-B1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER (US) | 2004-06-30 | — | — | EP | claimed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | claimed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | claimed |
| CN-1245490-A | Sulfonyl urea derivatives and their use in control of interleukin-1 activity | PFIZER (US) | 2000-02-23 | — | — | CN | claimed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | claimed |
| CN-116635373-B | Amide derivatives and use thereof | 康百达（四川）生物医药科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116635374-B | Amide derivatives and use thereof | 康百达（四川）生物医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113747925-B | Extracellular vesicle conjugates and uses thereof | 隆萨销售股份公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-118638081-A | Sulfonylurea compounds | 武汉科技大学 | 2024-09-13 | — | — | CN | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| CN-1245490-A | Sulfonyl urea derivatives and their use in control of interleukin-1 activity | PFIZER (US) | 2000-02-23 | — | — | CN | disclosed |
| CN-1244526-A | Effective synthetic method for furau sulfonic acid amide compound for synthesizing new IL-1 inhibitor | PFIZER PRODUCTS CO (US) | 2000-02-16 | — | — | CN | disclosed |
| US-6022984-A | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors | PFIZER INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0976742-A1 | A synthesis of furan sulfonamide compounds useful in the synthesis of IL-1 inhibitors | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | NLRP3 1/4885CA2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.